Multivalent bi-specific nanobioconjugate engager for targeted cancer immunotherapy

Hengfeng Yuan, Wen Jiang, Christina A. Von Roemeling, Yaqing Qie, Xiujie Liu, Yuanxin Chen, Yifan Wang, Robert E. Wharen, Kyuson Yun, Guojun Bu, Keith L. Knutson, Betty Y.S. Kim

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

Tumour-targeted immunotherapy offers the unique advantage of specific tumouricidal effects with reduced immune-associated toxicity. However, existing platforms suffer from low potency, inability to generate long-term immune memory and decreased activities against tumour-cell subpopulations with low targeting receptor levels. Here we adopted a modular design approach that uses colloidal nanoparticles as substrates to create a multivalent bi-specific nanobioconjugate engager (mBiNE) to promote selective, immune-mediated eradication of cancer cells. By simultaneously targeting the human epidermal growth factor receptor 2 (HER2) expressed by cancer cells and pro-phagocytosis signalling mediated by calreticulin, the mBiNE stimulated HER2-targeted phagocytosis and produced durable antitumour immune responses against HER2-expressing tumours. Interestingly, although the initial immune activation mediated by the mBiNE was receptor dependent, the subsequent antitumour immunity also generated protective effects against tumour-cell populations that lacked the HER2 receptor. Thus, the mBiNE represents a new targeted, nanomaterial-immunotherapy platform to stimulate innate and adaptive immunity and promote a universal antitumour response.

Original languageEnglish (US)
Pages (from-to)763-769
Number of pages7
JournalNature Nanotechnology
Volume12
Issue number8
DOIs
StatePublished - Aug 1 2017
Externally publishedYes

Fingerprint

Tumors
cancer
Cells
tumors
Calreticulin
immunity
Nanostructured materials
platforms
Toxicity
Chemical activation
Nanoparticles
Data storage equipment
human ERBB2 protein
Epidermal Growth Factor
toxicity
Substrates
activation
nanoparticles
cells

ASJC Scopus subject areas

  • Bioengineering
  • Atomic and Molecular Physics, and Optics
  • Biomedical Engineering
  • Materials Science(all)
  • Condensed Matter Physics
  • Electrical and Electronic Engineering

Cite this

Yuan, H., Jiang, W., Von Roemeling, C. A., Qie, Y., Liu, X., Chen, Y., ... Kim, B. Y. S. (2017). Multivalent bi-specific nanobioconjugate engager for targeted cancer immunotherapy. Nature Nanotechnology, 12(8), 763-769. https://doi.org/10.1038/nnano.2017.69

Multivalent bi-specific nanobioconjugate engager for targeted cancer immunotherapy. / Yuan, Hengfeng; Jiang, Wen; Von Roemeling, Christina A.; Qie, Yaqing; Liu, Xiujie; Chen, Yuanxin; Wang, Yifan; Wharen, Robert E.; Yun, Kyuson; Bu, Guojun; Knutson, Keith L.; Kim, Betty Y.S.

In: Nature Nanotechnology, Vol. 12, No. 8, 01.08.2017, p. 763-769.

Research output: Contribution to journalArticle

Yuan, H, Jiang, W, Von Roemeling, CA, Qie, Y, Liu, X, Chen, Y, Wang, Y, Wharen, RE, Yun, K, Bu, G, Knutson, KL & Kim, BYS 2017, 'Multivalent bi-specific nanobioconjugate engager for targeted cancer immunotherapy', Nature Nanotechnology, vol. 12, no. 8, pp. 763-769. https://doi.org/10.1038/nnano.2017.69
Yuan, Hengfeng ; Jiang, Wen ; Von Roemeling, Christina A. ; Qie, Yaqing ; Liu, Xiujie ; Chen, Yuanxin ; Wang, Yifan ; Wharen, Robert E. ; Yun, Kyuson ; Bu, Guojun ; Knutson, Keith L. ; Kim, Betty Y.S. / Multivalent bi-specific nanobioconjugate engager for targeted cancer immunotherapy. In: Nature Nanotechnology. 2017 ; Vol. 12, No. 8. pp. 763-769.
@article{e987d748ca464e4c8b26db071449171b,
title = "Multivalent bi-specific nanobioconjugate engager for targeted cancer immunotherapy",
abstract = "Tumour-targeted immunotherapy offers the unique advantage of specific tumouricidal effects with reduced immune-associated toxicity. However, existing platforms suffer from low potency, inability to generate long-term immune memory and decreased activities against tumour-cell subpopulations with low targeting receptor levels. Here we adopted a modular design approach that uses colloidal nanoparticles as substrates to create a multivalent bi-specific nanobioconjugate engager (mBiNE) to promote selective, immune-mediated eradication of cancer cells. By simultaneously targeting the human epidermal growth factor receptor 2 (HER2) expressed by cancer cells and pro-phagocytosis signalling mediated by calreticulin, the mBiNE stimulated HER2-targeted phagocytosis and produced durable antitumour immune responses against HER2-expressing tumours. Interestingly, although the initial immune activation mediated by the mBiNE was receptor dependent, the subsequent antitumour immunity also generated protective effects against tumour-cell populations that lacked the HER2 receptor. Thus, the mBiNE represents a new targeted, nanomaterial-immunotherapy platform to stimulate innate and adaptive immunity and promote a universal antitumour response.",
author = "Hengfeng Yuan and Wen Jiang and {Von Roemeling}, {Christina A.} and Yaqing Qie and Xiujie Liu and Yuanxin Chen and Yifan Wang and Wharen, {Robert E.} and Kyuson Yun and Guojun Bu and Knutson, {Keith L.} and Kim, {Betty Y.S.}",
year = "2017",
month = "8",
day = "1",
doi = "10.1038/nnano.2017.69",
language = "English (US)",
volume = "12",
pages = "763--769",
journal = "Nature Nanotechnology",
issn = "1748-3387",
publisher = "Nature Publishing Group",
number = "8",

}

TY - JOUR

T1 - Multivalent bi-specific nanobioconjugate engager for targeted cancer immunotherapy

AU - Yuan, Hengfeng

AU - Jiang, Wen

AU - Von Roemeling, Christina A.

AU - Qie, Yaqing

AU - Liu, Xiujie

AU - Chen, Yuanxin

AU - Wang, Yifan

AU - Wharen, Robert E.

AU - Yun, Kyuson

AU - Bu, Guojun

AU - Knutson, Keith L.

AU - Kim, Betty Y.S.

PY - 2017/8/1

Y1 - 2017/8/1

N2 - Tumour-targeted immunotherapy offers the unique advantage of specific tumouricidal effects with reduced immune-associated toxicity. However, existing platforms suffer from low potency, inability to generate long-term immune memory and decreased activities against tumour-cell subpopulations with low targeting receptor levels. Here we adopted a modular design approach that uses colloidal nanoparticles as substrates to create a multivalent bi-specific nanobioconjugate engager (mBiNE) to promote selective, immune-mediated eradication of cancer cells. By simultaneously targeting the human epidermal growth factor receptor 2 (HER2) expressed by cancer cells and pro-phagocytosis signalling mediated by calreticulin, the mBiNE stimulated HER2-targeted phagocytosis and produced durable antitumour immune responses against HER2-expressing tumours. Interestingly, although the initial immune activation mediated by the mBiNE was receptor dependent, the subsequent antitumour immunity also generated protective effects against tumour-cell populations that lacked the HER2 receptor. Thus, the mBiNE represents a new targeted, nanomaterial-immunotherapy platform to stimulate innate and adaptive immunity and promote a universal antitumour response.

AB - Tumour-targeted immunotherapy offers the unique advantage of specific tumouricidal effects with reduced immune-associated toxicity. However, existing platforms suffer from low potency, inability to generate long-term immune memory and decreased activities against tumour-cell subpopulations with low targeting receptor levels. Here we adopted a modular design approach that uses colloidal nanoparticles as substrates to create a multivalent bi-specific nanobioconjugate engager (mBiNE) to promote selective, immune-mediated eradication of cancer cells. By simultaneously targeting the human epidermal growth factor receptor 2 (HER2) expressed by cancer cells and pro-phagocytosis signalling mediated by calreticulin, the mBiNE stimulated HER2-targeted phagocytosis and produced durable antitumour immune responses against HER2-expressing tumours. Interestingly, although the initial immune activation mediated by the mBiNE was receptor dependent, the subsequent antitumour immunity also generated protective effects against tumour-cell populations that lacked the HER2 receptor. Thus, the mBiNE represents a new targeted, nanomaterial-immunotherapy platform to stimulate innate and adaptive immunity and promote a universal antitumour response.

UR - http://www.scopus.com/inward/record.url?scp=85018454897&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85018454897&partnerID=8YFLogxK

U2 - 10.1038/nnano.2017.69

DO - 10.1038/nnano.2017.69

M3 - Article

C2 - 28459470

AN - SCOPUS:85018454897

VL - 12

SP - 763

EP - 769

JO - Nature Nanotechnology

JF - Nature Nanotechnology

SN - 1748-3387

IS - 8

ER -